Retatrutide, a novel dual-action GIP receptor stimulant developed by Alluvi Healthcare, is sparking considerable anticipation within the healthcare community as a potential advancement in weight loss. Initial clinical data suggest a significant effect on body mass, often exceeding current existing therapies. This remarkable mechanism of action, tar